Skip to main content

Table 2 Results of a meta-analysis

From: Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies

Outcome of interest

No. of studies

No.of

patients

Results

OR/WMD

95% CI

P-value

I2 (%)

Patients characteristics

       

   Age (years)

       

B-HCC versus C-HCC

15 [3, 4, 26–34, 36, 39, 41, 42]

3281

B-HCC = 54.4 ± 9.2, C-HCC = 64.3 ± 6.8

-10.11

-11.14, -9.09

< 0.001

65.3

B-HCC versus NBNC-HCC

11 [3, 4, 26, 27, 29, 31–33, 39, 41]

1169

B-HCC = 53.7 ± 8.5, NBNC-HCC = 63.7 ± 7.7

-10.42

-12.72, -8.12

< 0.001

86.1

C-HCC versus NBNC-HCC

11 [3, 4, 26, 27, 29, 31–33, 39, 41]

1528

C-HCC = 64.2 ± 6.4, NBNC-HCC = 63.7 ± 7.7

0.08

-2.18, 2.38

0.95

88.2

   Male

       

B-HCC versus C-HCC

19 [3–5, 26–31, 33–42]

4198

B-HCC = 82.6%, C-HCC = 75.8%

1.19

0.89, 1.60

0.24

61.2

B-HCC versus NBNC-HCC

14 [3–5, 26–29, 31, 33, 35, 37–39, 41]

1562

B-HCC = 81.4%, NBNC-HCC = 74.5%

1.43

1.10, 1.86

0.008

16.3

C-HCC versus NBNC-HCC

14 [3–5, 26–29, 31, 33, 35, 37–39, 41]

1967

C-HCC = 75.9%, NBNC-HCC = 74.5%

0.96

0.74, 1.23

0.74

31

Liver function

       

   Serum ALT level (IU/l)

       

B-HCC versus C-HCC

11 [3, 4, 27, 29, 30, 32–34, 36, 39, 41]

1909

B-HCC = 56.4 ± 44.8, C-HCC = 76.9 ± 47.6

-16.84

-21.02, -12.65

< 0.001

23.4

B-HCC versus NBNC-HCC

8 [3, 4, 27, 29, 32, 33, 39, 41]

842

B-HCC = 56.7 ± 55.9, NBNC-HCC = 39.6 ± 31.1

15.30

4.59, 26.01

0.005

73.9

C-HCC versus NBNC-HCC

8 [3, 4, 27, 29, 32, 33, 39, 41]

1122

C-HCC = 74.1 ± 43.8, NBNC-HCC = 39.6 ± 31.1

34.41

23.75, 45.08

< 0.001

84.9

   Serum AST level (IU/l)

       

B-HCC versus C-HCC

8 [3, 4, 29, 30, 32, 33, 39, 41]

842

B-HCC = 60.0 ± 56.7, C-HCC = 70.8 ± 38.1

-13.17

-22.29, -4.05

0.005

61.5

B-HCC versus NBNC-HCC

7 [3, 4, 29, 32, 33, 39, 41]

537

B-HCC = 61.0 ± 55.9, NBNC-HCC = 43.8 ± 25.5

13.06

0.13, 26.00

0.05

72.8

C-HCC versus NBNC-HCC

7 [3, 4, 29, 32, 33, 39, 41]

993

C-HCC = 69.9 ± 37.7, NBNC-HCC = 43.8 ± 25.5

24.87

18.94, 30.79

< 0.001

56.5

   Serum albumin level (g/dl)

       

B-HCC versus C-HCC

10 [3, 27, 29–31, 33, 34, 36, 39, 41]

1834

B-HCC = 3.93 ± 0.48, C-HCC = 3.69 ± 0.48

0.23

0.08, 0.38

0.002

87.4

B-HCC versus NBNC-HCC

7 [3, 27, 29, 31, 33, 39, 41]

707

B-HCC = 3.91 ± 0.45, NBNC-HCC = 3.94 ± 0.48

-0.07

-0.15, 0.00

0.07

36.4

C-HCC versus NBNC-HCC

7 [3, 27, 29, 31, 33, 39, 41]

1136

C-HCC = 3.61 ± 0.47, NBNC-HCC = 3.94 ± 0.48

-0.29

-0.53, -0.05

0.002

89.7

   ICG R15 (%)

       

B-HCC versus C-HCC

10 [3, 4, 26, 31–33, 36, 39, 41]

1740

B-HCC = 12.9 ± 7.8, C-HCC = 20.4 ± 9.1

-6.58

-8.3, -4.87

< 0.001

78.9

B-HCC versus NBNC-HCC

8 [3, 4, 26, 31–33, 39, 41]

699

B-HCC = 12.8 ± 7.5, NBNC-HCC = 13.9 ± 7.7

-0.74

-1.77, -0.30

0.16

21.3

C-HCC versus NBNC-HCC

8 [3, 4, 26, 31–33, 39, 41]

1081

C-HCC = 21.0 ± 9.0, NBNC-HCC = 13.9 ± 7.7

5.92

3.85, 7.99

< 0.001

74.3

   Child's grade A

       

B-HCC versus C-HCC

9 [4, 5, 27, 28, 32, 35, 38, 40, 42]

2434

B-HCC = 88.3%, C-HCC = 80.8%

1.68

1.25, 2.25

< 0.001

34.9

B-HCC versus NBNC-HCC

7 [4, 5, 27, 28, 32, 35, 38]

956

B-HCC = 79.4%, NBNC-HCC = 80.6%

1.31

0.87, 1.98

0.20

0

C-HCC versus NBNC-HCC

7 [4, 5, 27, 28, 32, 35, 38]

804

C-HCC = 78.4%, NBNC-HCC = 80.6%

0.69

0.46, 1.05

0.08

1.1

   Serum T-Bil level (mg/dL)

       

B-HCC versus C-HCC

9 [4, 27, 29–31, 33, 36, 39, 41]

1579

B-HCC = 0.91 ± 0.47, C-HCC = 1.23 ± 0.83

-0.14

-0.27, -0.01

0.03

80.1

B-HCC versus NBNC-HCC

6 [4, 27, 29, 31, 39, 41]

766

B-HCC = 0.92 ± 0.47, NBNC-HCC = 0.87 ± 0.49

0.06

-0.16, 0.28

0.60

90.3

C-HCC versus NBNC-HCC

6 [4, 27, 29, 31, 39, 41]

816

C-HCC = 1.18 ± 0.76, NBNC-HCC = 0.87 ± 0.49

0.25

-0.02, 0.52

0.07

90.6

   Serum platelet count (×103/mm)

       

B-HCC versus C-HCC

7 [27, 29, 30, 33, 34, 39, 41]

1230

B-HCC = 166.6 ± 85.0, C-HCC = 137.5 ± 66.9

24.47

1.24, 47.7

0.04

82.1

B-HCC versus NBNC-HCC

5 [27, 29, 33, 39, 41]

609

B-HCC = 156.8 ± 73.4, NBNC-HCC = 192.2 ± 72.4

-28.88

-41.93, -15.83

< 0.001

30.9

C-HCC versus NBNC-HCC

5 [27, 29, 33, 39, 41]

822

C-HCC = 138.2 ± 66.6, NBNC-HCC = 192.2 ± 72.4

-50.43

-75.13, -25.72

< 0.001

74.8

Tumor characteristics

       

Size (cm)

       

B-HCC versus C-HCC

10 [3, 26, 27, 29, 30, 33, 34, 36, 39, 41]

1879

B-HCC = 5.4 ± 2.5, C-HCC = 4.0 ± 2.1

1.32

0.38, 2.27

0.006

98.4

B-HCC versus NBNC-HCC

7 [3, 26, 27, 29, 33, 39, 41]

827

B-HCC = 5.1 ± 2.5, NBNC-HCC = 5.3 ± 2.6

-0.02

-0.94, 0.00

0.97

96.5

C-HCC versus NBNC-HCC

7 [3, 26, 27, 29, 33, 39, 41]

1103

C-HCC = 3.8 ± 2.2, NBNC-HCC = 5.3 ± 2.6

-0.86

-1.27, -0.45

< 0.001

78.1

   Coexisting cirrhosis

       

B-HCC versus C-HCC

15 [3, 4, 26–32, 34–38, 40–42]

3623

B-HCC = 53.4%, C-HCC = 65.7%

0.71

0.54, 0.92

0.01

55.5

B-HCC versus NBNC-HCC

12 [3, 4, 26–29, 31, 32, 35, 37, 38, 41]

1190

B-HCC = 61.8%, NBNC-HCC = 45.5%

2.61

1.56, 4.64

< 0.001

63.1

C-HCC versus NBNC-HCC

12 [3, 4, 26–29, 31, 32, 35, 37, 38, 41]

1454

C-HCC = 69.9%, NBNC-HCC = 45.5%

3.92

2.35, 6.53

< 0.001

56.4

   Vascular invasion

       

B-HCC versus C-HCC

17 [3–5, 26–30, 34–42]

3760

B-HCC = 46.2%, C-HCC = 34.4%

1.29

0.97, 1.73

0.08

61.2

B-HCC versus NBNC-HCC

12 [3–5, 26–29, 35, 37–39, 42]

1454

B-HCC = 31.9%, NBNC-HCC = 32.9%

1.44

0.99, 2.11

0.06

37.5

C-HCC versus NBNC-HCC

12 [3–5, 26–29, 35, 37–39, 42]

1579

C-HCC = 28.7%, NBNC-HCC = 32.9%

0.99

0.62, 1.56

0.96

59.0

   Intrahepatic metastases/satellite nodules

       

B-HCC versus C-HCC

11 [4, 26, 28–31, 35, 37–40]

1836

B-HCC = 31%, C-HCC = 24.5%

1.23

0.87, 1.73

0.24

42.0

B-HCC versus NBNC-HCC

9 [4, 26, 28, 29, 31, 35, 37–39]

726

B-HCC = 30.3%, NBNC-HCC = 28.8%

1.01

0.56, 1.83

0.97

49.9

C-HCC versus NBNC-HCC

9 [4, 26, 28, 29, 31, 35, 37–39]

1030

C-HCC = 24.4%, NBNC-HCC = 28.8%

0.98

0.69, 1.39

0.91

23.8

   Capsule formation

       

B-HCC versus C-HCC

8 [4, 26, 27, 29, 30, 36, 38, 39]

1509

B-HCC = 47.7%, C-HCC = 53.8%

0.86

0.57, 1.29

0.46

53.8

B-HCC versus NBNC-HCC

6 [4, 26, 27, 29, 38, 39]

786

B-HCC = 49.3%, NBNC-HCC = 47.9%

0.96

0.55, 1.67

0.88

51.1

C-HCC versus NBNC-HCC

6 [4, 26, 27, 29, 38, 39]

725

C-HCC = 52.1%, NBNC-HCC = 47.9%

1.10

0.77, 1.57

0.60

18.9

   Serum AFP level (ng/ml)

       

B-HCC versus C-HCC

9 [3, 28–31, 33, 34, 36, 41]

1611

B-HCC = 11555.3 ± 45653.8, C-HCC = 2496.0 ± 9014.5

-52.96

-281.61, 175.69

0.65

39.5

B-HCC versus NBNC-HCC

6 [3, 28, 29, 31, 33, 41]

458

B-HCC = 13927.5 ± 56323.0, NBNC-HCC = 3069.1 ± 9330.6

1385.80

-1099.05, 3870.66

0.27

86.8

C-HCC versus NBNC-HCC

6 [3, 28, 29, 31, 33, 41]

1064

C-HCC = 2181.0 ± 8052.8, NBNC-HCC = 3069.1 ± 9330.6

-214.61

-714.20, 284.98

0.40

0

Survival

       

   5-year overall survival

       

B-HCC versus C-HCC

14 [3–5, 26–28, 30, 34–36, 38, 40–42]

3427

B-HCC = 51.4%, C-HCC = 52.9%

1.00

0.76, 1.31

0.99

61.9

B-HCC versus NBNC-HCC

9 [3–5, 26–28, 35, 38, 41]

1289

B-HCC = 50.2%, NBNC-HCC = 53.0%

0.68

0.44, 1.06

0.09

55.8

C-HCC versus NBNC-HCC

9 [3–5, 26–28, 35, 38, 41]

1239

C-HCC = 49.0%, NBNC-HCC = 53.0%

0.61

0.33, 1.11

0.10

75.7

   5-year disease-free survival

       

B-HCC versus C-HCC

13 [3, 4, 26, 28–30, 34, 35, 37–41]

2113

B-HCC = 32.3%, C-HCC = 25.5%

1.46

0.88, 2.41

0.14

77.8

B-HCC versus NBNC-HCC

10 [3, 4, 26, 28, 29, 35, 37–39, 41]

860

B-HCC = 28.7%, NBNC-HCC = 49.3%

0.39

0.28, 0.53

< 0.001

33.4

C-HCC versus NBNC-HCC

10 [3, 4, 26, 28, 29, 35, 37–39, 41]

1245

C-HCC = 26.8%, NBNC-HCC = 49.3%

0.37

0.22, 0.64

< 0.001

69.4

  1. OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; HCC = hepatocellular carcinoma; B-HCC = hepatitis B-related hepatocellular carcinoma; C-HCC = hepatitis C-related hepatocellular carcinoma; NBNC-HCC = no infection of HBV or HCV related hepatocellular carcinoma; AFP = alpha fetoprotein; ALT = alanine aminotransferase; AST = aspartate aminotransferase; T-Bil = total bilirubin; ICG R15 = indocyanine green retention rate at 15 minutes.
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us